

### REFERENCES

1. Erichsen MM, Løvås K, Fougner KJ, et al. Normal overall mortality rate in Addison's disease, but young patients are at risk of premature death. *Eur J Endocrinol* 2009; 160:233–237.
2. Oelkers W. Adrenal insufficiency. *N Engl J Med* 1996; 335:1206–1212.
3. Redman BG, Pazdur R, Zingas AP, Loredó R. Prospective evaluation of adrenal insufficiency in patients with adrenal metastasis. *Cancer* 1987; 60:103–107.
4. Berger M. Hypofunction of the adrenal cortex in infancy. *Manit Med Rev* 1949; 29:132.
5. Stulberg DL, Clark N, Tovey D. Common hyperpigmentation disorders in adults: Part I. Diagnostic approach, café au lait macules, diffuse hyperpigmentation, sun exposure, and phototoxic reactions. *Am Fam Physician* 2003; 68:1955–1960.
6. Zelissen PM, Bast EJ, Croughs RJ. Associated autoimmunity in Addison's disease. *J Autoimmun* 1995; 8:121–130.
7. Lutz A, Stojkovic M, Schmidt M, Arlt W, Allolio B, Reincke M. Adrenocortical function in patients with macrometastases of the adrenal gland. *Eur J Endocrinol* 2000; 143:91–97.
8. Kung AW, Pun KK, Lam K, Wang C, Leung CY. Addisonian crisis as presenting feature in malignancies. *Cancer* 1990; 65:177–179.
9. Cedermark BJ, Sjöberg HE. The clinical significance of metastases to the adrenal glands. *Surg Gynecol Obstet* 1981; 152:607–610.
10. Rosenthal FD, Davies MK, Burden AC. Malignant disease presenting as Addison's disease. *Br Med J* 1978; 1:1591–1592.
11. Seidenwurm DJ, Elmer EB, Kaplan LM, Williams EK, Morris DG, Hoffman AR. Metastases to the adrenal glands and the development of Addison's disease. *Cancer* 1984; 54:552–557.
12. Santiago AH, Ratzan S. Acute adrenal crisis in an asthmatic child treated with inhaled fluticasone propionate. *Int J Pediatr Endocrinol* 2010; 2010. pii:749239.
13. Holme J, Tomlinson JW, Stockley RA, Stewart PM, Barlow N, Sullivan AL. Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. *Eur Respir J* 2008; 32:1047–1052.
14. Mohammad K, Sadikot RT. Adrenal insufficiency as a presenting manifestation of nonsmall cell lung cancer. *South Med J* 2009; 102:665–667.

ADDRESS: Khaldoon Shaheen, MD, 4151 Westbrook Drive, Brooklyn, OH 44144; e-mail khaldoonshaheen@yahoo.com.

### CORRECTION

An error appeared in “Advances in the management of PML: focus on natalizumab” (Fox R. *Cleve Clin J Med* 2011; 78[Suppl 2]:S33–S37), in the November 2011 supplement to the *Cleveland Clinic Journal of Medicine, Progressive Multifocal Leukoencephalopathy in the Biologic Era: Implications for Practice*. On page S34, in the section “Experience with natalizumab,” the second sentence of the second paragraph included an incorrect percentage. The corrected paragraph appears below. The error has been corrected in the online version of the article.

“The mortality associated with natalizumab-related PML was 19% (29 deaths among the 150 confirmed cases) as of August 4, 2011.<sup>3</sup> In cases with at least 6 months of follow-up, mortality has remained at about

20%. Many who survived were left with serious morbidity and permanent disability, although interpretation of disability is difficult because functional impairment is a hallmark of multiple sclerosis (MS) irrespective of PML. Survival in patients with natalizumab-associated PML appears to be better than with PML associated with other conditions, possibly because of early diagnosis achieved through clinical vigilance and swift immune reconstitution through natalizumab discontinuation and either plasmapheresis or immunoabsorption. Predictors of survival include younger age at diagnosis, less disability prior to onset of PML, more localized disease on magnetic resonance imaging (MRI) of the brain, and shorter time from symptom onset to PML diagnosis.”